UnionPay Announces Partnership With Fast Growing Digital Platform Glovo
UnionPay International, the card payment organisation with the world’s largest cardholder base, today announces a partnership with Glovo, the Barcelona-based on-demand economy technology start-up, which enables UnionPay cardholders to use its app initially in Spain, Portugal, France and Italy.
Founded in 2015, Glovo is an on-demand economy technology start-up that allows local stores to offer their products in the same city through the GLOVO App and supports intermediates in the delivery of such products. It is currently present in 22 countries including Croatia, France, Georgia, Italy, Poland, Portugal, Romania, Serbia, Spain and Ukraine.
This new partnership with Glovo enables UnionPay cardholders to make a wider range of purchases without the need to leave home. To encourage take up of the service while some lockdown measures are still in place, UnionPay customers have been offered free delivery until 15 August in Spain, Portugal and France.
UnionPay acceptance in France, Italy, Portugal and Spain has grown significantly in the last 12 months with a large number of online and offline merchants now accepting UnionPay cards. UnionPay’s cardholder base comprises Chinese ex-pats living and working in Europe, students from Asian countries, as well as a rapidly increasing domestic customer base among European nationals. This is particularly the case in Portugal where last year Millennium bcp became the first European bank to issue UnionPay cards.
Wei Zhihong, UnionPay International’s Market Director and Head of Europe said: “As one of the largest bankcard schemes worldwide, we are committed to providing payment ease for our cardholders. In this difficult time, we are making an extra effort, together with our partners, to offer safer and easier services to support our cardholders in Europe. We are very pleased to have reached a partnership with one of the world’s leading on-demand economy technology start-ups. Glovo is a company which has grown rapidly since its foundation in 2015 and through this new partnership the reach of its app is extended to our cardholders.
“With consumer behaviour changing as a result of COVID-19, more people are staying indoors and making purchases. This new partnership will enable our customers to benefit from Glovo’s platform and service, making purchases and arranging pick-ups without having to leave their own home. We are happy that we have been able to agree a delivery fee free period with Glovo to help keep costs down for cardholders. We look forward to announcing many more similar partnerships in the very near future.”
Sacha Michaud, Co-founder of Glovo said: “We are delighted to have reached a new partnership with UnionPay and hope that it represents the beginning of a long-term relationship which will benefit UnionPay card holders throughout France, Italy, Portugal and Spain. We look forward to working together on further partnerships as we move forward.”
With over 8.4 billion cards accumulatively issued worldwide, UnionPay is the card payment organisation with the world’s largest cardholder base. Its global network extends to 179 countries and regions, covering over 52 million merchants and more than 2.9 million ATMs worldwide.
- Ends -
About UnionPay International
UnionPay International (UPI) is a subsidiary of China UnionPay focused on the growth and support of UnionPay’s global business. In partnership with more than 2300 institutions worldwide, UnionPay
International has enabled card acceptance in 179 countries and regions with issuance in 61 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.
For more information, please visit: www.unionpayintl.com/en
For media enquiries please contact:
Citigate Dewe Rogerson
Oliver Parry/ Brandon Stockwell/ Patrick Evans
unionpay@citigatedewerogerson.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005031/en/
Contact information
For media enquiries please contact:
Citigate Dewe Rogerson
Oliver Parry/ Brandon Stockwell/ Patrick Evans
unionpay@citigatedewerogerson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom